Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Does hormone therapy affect IBD outcomes in transgender, nonbinary patients?
Disease activity, as measured by C-reactive protein (CRP), foecal calprotectin (FC), and endoscopic evaluation, does not significantly vary a year following the initiation of gender-affirming hormone (GAH) therapy in transgender and gender nonconforming patients with inflammatory bowel disease (IBD), as shown in a study presented at AIBD 2024.
Does hormone therapy affect IBD outcomes in transgender, nonbinary patients?
15 Jan 2025
Survival benefit with STRIDE for HCC sustained at 5 years
The updated exploratory analysis of the phase III HIMALAYA trial demonstrates a significant overall survival (OS) benefit at 5 years with the STRIDE* regimen comprising tremelimumab and durvalumab for patients with unresectable hepatocellular carcinoma (HCC).
Survival benefit with STRIDE for HCC sustained at 5 years
10 Jan 2025
Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer
The first interim analysis of the phase III LEAP-012 study shows the potential of lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) as a new treatment option for intermediate-stage hepatocellular carcinoma (HCC).
